The Company has analyzed the preliminary immune response data from FLAMINGO-01. Immune response data in both the HLA-A*02 treated and placebo arms and the third open label arm with all other HLA types ...
Final Phase 2 data show casdozokitug with atezolizumab/bevacizumab achieves a 17.2% complete response rate in HCC patients. Coherus BioSciences, Inc. announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback